Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Inclusion criteria

• 18≤Age≤45, male or female;
• Body weight (> 45.0 kg (female) or 50.0 kg (male), 19.0 kg/m2 (< BMI) = 26.0 kg/m2);
• Subjects with normal clinical significance by medical history, vital signs, physical examination and laboratory examination;
• All subjects who adopt effective non-hormonal contraceptive measures (such as condoms, intrauterine devices without drugs, etc.) from the signing of informed consent to three months after the end of the study;
• Subjects who voluntarily signed the informed consent and are able to cooperate to complete the test according to the protocal.

Exclusion criteria

• Female subjects: pregnant or lactating, or planned pregnancy; male subjects: their partner planned pregnancy, or planned to donate sperm;
• Have neurological or psychiatric diseases history, or have serious cardiovascular, liver and kidney, endocrine, respiratory, blood, digestive, immune and other systemic diseases history;
• Surgery history within six months before signing the informed consent;
• Allergic history to more than one drug or other serious allergic rhistory.
• Subjects with a QTc interval greater than 450 ms (male) or 470 MS (female), or with a history of prolonged QTc interval;
• Positive with serum immunological test for HBsAg, Anti-HCV, Anti-HIV or Anti-TP;
• History of drugs or drug abuse or alcoholics;
• History of blood donation more than 200 mL within 8 weeks before signing informed consent;
• Subjects participating in other clinical trials, or who have participated in any other clinical trials of drugs within three months before signing informed consent;
• Not suitable for this trial according to the investigator.